Provided by Tiger Trade Technology Pte. Ltd.

IQVIA

259.82
+3.771.47%
Post-market: 259.820.00000.00%19:30 EDT
Volume:1.31M
Turnover:338.29M
Market Cap:42.77B
PE:32.19
High:260.40
Open:256.79
Low:254.93
Close:256.05
52wk High:260.40
52wk Low:154.50
Shares:164.60M
Float Shares:151.00M
Volume Ratio:1.00
T/O Rate:0.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):8.07
EPS(LYR):7.84
ROE:22.82%
ROA:5.06%
PB:6.93
PE(LYR):33.14

Loading ...

Assessing IQVIA Holdings (IQV) Valuation After Expanded AI Clinical Trial Collaboration With Kexing Biopharm

Simply Wall St.
·
May 14

Iqvia, Kexing expand strategic collaboration

TIPRANKS
·
May 14

IQVIA Holdings Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
May 14

Gartner Inc. Stock Slips 5.6%, Underperforms Peers

Dow Jones
·
May 14

IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development Using AI-Enabled Capabilities

THOMSON REUTERS
·
May 14

IQVIA Holdings Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
May 12

Fosun unit Henlius wins FDA go-ahead for HLX05-N colorectal cancer trial

Reuters
·
May 10

US Prescriptions for Lilly's Foundayo Were 7,335 for Week Ended May 1 - IQVIA Data Shared by Analyst Shows

THOMSON REUTERS
·
May 08

Iqvia approves $2B increase to share repurchase authorization

TIPRANKS
·
May 08

IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization

THOMSON REUTERS
·
May 08

IQVIA Holdings Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
May 08

Iqvia price target lowered to $225 from $240 at Morgan Stanley

TIPRANKS
·
May 08

Charles River beats quarterly estimates on steady demand for drug development services

Reuters
·
May 07

Gartner Inc. Stock Rises Wednesday, Still Underperforms Market

Dow Jones
·
May 07

IQVIA CFO Mike Fedock speaks at Bank of America Health Care Conference

Reuters
·
May 07

IQVIA's Growth Setup Looks Positive After Q1 Beat, RBC Says

MT Newswires Live
·
May 07

IQVIA: Buy Rating Reiterated on Resilient Fundamentals and AI-Driven Growth Despite Price Target Cut to $210

TIPRANKS
·
May 07

Analysts Offer Insights on Healthcare Companies: DaVita (DVA), IQVIA Holdings (IQV) and Climb Bio (CLYM)

TIPRANKS
·
May 06

Barclays Sticks to Their Buy Rating for IQVIA Holdings (IQV)

TIPRANKS
·
May 06

IQVIA: Buy Rating Reaffirmed, $213 Price Target Maintained on Solid B2B Momentum and Margin Outlook

TIPRANKS
·
May 06